Erbb3 Products By Gene Name

377-HB) stimulates proliferation in the MCF-17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND₅₀ is typically 0.0075-0.03 µg/mL." class="big_lightbox"> 377-HB) stimulates proliferation in the MCF-17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND₅₀ is typically 0.0075-0.03 µg/mL." alt="Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (Catalog # 377-HB) stimulates proliferation in the MCF-17 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-1 beta 1/HRG1-1 beta 1 (10 ng/mL) is neutralized (green line) by increasing concentrations of Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481). The ND₅₀ is typically 0.0075-0.03 µg/mL." class="big_thumb" />

348-RB) was serially diluted and captured by Mouse Anti-Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human ErbB3/Her3 Biotinylated Monoclonal Antibody (Catalog # [[catalogNumber:) was incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # [[catalogNumber:DY998)" class="big_lightbox"> 348-RB) was serially diluted and captured by Mouse Anti-Human ErbB3/Her3 Monoclonal Antibody (Catalog # MAB3481) coated on a Clear Polystyrene Microplate (Catalog # DY990). Mouse Anti-Human ErbB3/Her3 Biotinylated Monoclonal Antibody (Catalog # [[catalogNumber:) was incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # [[catalogNumber:DY998)" class="big_thumb" />

HAF019). A specific band was detected for ErbB3/Her3 at approximately 180kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8." class="big_lightbox"> HAF019). A specific band was detected for ErbB3/Her3 at approximately 180kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8." alt="Western blot shows lysates of MCF-7 human breast cancer cell line. PVDF Membrane was probed with 1 µg/mL of Goat Anti-Human ErbB3/Her3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF234) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for ErbB3/Her3 at approximately 180kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8." class="big_thumb" />

377-HB) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human ErbB3/Her3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF234). The ND₅₀ is typically 0.125-0.5 µg/mL." class="big_lightbox"> 377-HB) stimulates proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human NRG1-beta 1/HRG1-beta 1 Extracellular Domain (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human ErbB3/Her3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF234). The ND₅₀ is typically 0.125-0.5 µg/mL." class="big_thumb" />

5-001-A, open histogram), followed by Allophycocyanin-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # F0127)." class="big_lightbox"> 5-001-A, open histogram), followed by Allophycocyanin-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # F0127)." alt="C2C12 mouse myoblast cell line was stained with Sheep Anti-Mouse ErbB3/Her3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4518, filled histogram) or control antibody (Catalog # 5-001-A, open histogram), followed by Allophycocyanin-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # F0127)." class="big_thumb" />

NL010) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox"> NL010) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

NL010) and counterstained with DAPI (blue). View our protocol for Fluorescent IHC Staining of Frozen Tissue Sections." class="big_lightbox"> NL010) and counterstained with DAPI (blue). View our protocol for Fluorescent IHC Staining of Frozen Tissue Sections." class="big_thumb" />

396-HB) for 5 minutes. PVDF membrane was probed with 1 µg/mL of Human Phospho-ErbB3/Her3 (Y1262) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5817), followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-ErbB3/Her3 (Y1262) at approximately 185 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox"> 396-HB) for 5 minutes. PVDF membrane was probed with 1 µg/mL of Human Phospho-ErbB3/Her3 (Y1262) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5817), followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-ErbB3/Her3 (Y1262) at approximately 185 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of MDA-MB-453 human breast cancer cell line untreated (-) or treated (+) with 300 ng/mL Recombinant Human NRG1-beta /HRG1-beta (Catalog # 396-HB) for 5 minutes. PVDF membrane was probed with 1 µg/mL of Human Phospho-ErbB3/Her3 (Y1262) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5817), followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-ErbB3/Her3 (Y1262) at approximately 185 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

396-HB) for five minutes to induce tyrosine phosphorylation of ErbB3. Serial dilutions of lysates were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). For IP-Westerns, IPs were done using anti-ErbB3 monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with biotinylated anti-phosphotyrosine monoclonal antibody (Cat # BAM1676) to detect phospho-ErbB3. Bands were visualized with Streptavidin-HRP (Cat # DY998) followed by ECL detection. ErbB3 was observed at its predicted size (inset; 185 kDa, arrow) in Western blot analysis." class="big_lightbox"> 396-HB) for five minutes to induce tyrosine phosphorylation of ErbB3. Serial dilutions of lysates were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). For IP-Westerns, IPs were done using anti-ErbB3 monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with biotinylated anti-phosphotyrosine monoclonal antibody (Cat # BAM1676) to detect phospho-ErbB3. Bands were visualized with Streptavidin-HRP (Cat # DY998) followed by ECL detection. ErbB3 was observed at its predicted size (inset; 185 kDa, arrow) in Western blot analysis." alt="The human breast cancer cell line, MDA-MB-453, was treated with 100 ng/mL recombinant HRG-beta 1 (Catalog # 396-HB) for five minutes to induce tyrosine phosphorylation of ErbB3. Serial dilutions of lysates were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). For IP-Westerns, IPs were done using anti-ErbB3 monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with biotinylated anti-phosphotyrosine monoclonal antibody (Cat # BAM1676) to detect phospho-ErbB3. Bands were visualized with Streptavidin-HRP (Cat # DY998) followed by ECL detection. ErbB3 was observed at its predicted size (inset; 185 kDa, arrow) in Western blot analysis." class="big_thumb" />

396-HB) for five minutes. Cell lysates (100 μg) were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). IP-Western blots for phospho-ErbB3 (p-ErbB3) were done as described in Figure 1. Blots were stripped and total ErbB3 (ErbB3) was detected using biotinylated anti-ErbB3 polyclonal antibody (Catalog # BAF234). " class="big_lightbox"> 396-HB) for five minutes. Cell lysates (100 μg) were analyzed by R&D Systems’ Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769) and by IP-Western blot (inset). IP-Western blots for phospho-ErbB3 (p-ErbB3) were done as described in Figure 1. Blots were stripped and total ErbB3 (ErbB3) was detected using biotinylated anti-ErbB3 polyclonal antibody (Catalog # BAF234). " class="big_thumb" />

396-HB) for five minutes. The indicated amounts of ErbB3 (Catalog # 348-ER), ErbB2 (Catalog # 1129-ER) or EGF R (Catalog # 1095-ER) recombinant extracellular domains were added to 5 μg lysate and analyzed using R&D Systems’ Human Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769). Competition was observed only with recombinant ErbB3. " class="big_lightbox"> 396-HB) for five minutes. The indicated amounts of ErbB3 (Catalog # 348-ER), ErbB2 (Catalog # 1129-ER) or EGF R (Catalog # 1095-ER) recombinant extracellular domains were added to 5 μg lysate and analyzed using R&D Systems’ Human Phospho-ErbB3 DuoSet IC ELISA (Catalog # DYC1769). Competition was observed only with recombinant ErbB3. " class="big_thumb" />